Skip to main content
. 2023 Jun 1;13(9):3782–3801. doi: 10.1016/j.apsb.2023.05.034

Figure 3.

Figure 3

Inhibitory effect of SMU-Y6 on inflammatory cytokines in human and murine cell lines. (A) TNF-α and (B) IL-1β in supernatants of primary PBMCs after treatment with Pam3CSK4 (100 ng/mL) and different concentrations of SMU-Y6 for 24 h. (C) CCL5 in the supernatants of murine peritoneal macrophage after treatment with indicated Pam3CSK4 (100 ng/mL) and differing concentrations of SMU-Y6 for 24 h. (D) Pro-inflammatory NO in murine peritoneal macrophage after treatment with Pam3CSK4 (100 ng/mL), IFN-γ (40 ng/mL) and differing concentrations of SMU-Y6 for 24 h. (E) IL-6 in supernatants of BMDC after treatment with indicated Pam3CSK4 (100 ng/mL) and differing concentrations of SMU-Y6 for 24 h. (F) Pro-inflammatory NO in murine BMDCs after treatment with indicated Pam3CSK4 (100 ng/mL), IFN-γ (40 ng/mL) and different concentrations of SMU-Y6 for 24 h. Data presented is mean ± SD and the figures shown are representative of three independent experiments.

HHS Vulnerability Disclosure